Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced Pancreatic Cancer - MPR
Links shared publicly online about this topic.
- 238total visits
Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced Pancreatic Cancer - MPR
empr.com —
Data from the BAYPAN study presented at the American College of Clinical Oncology’s 2011 Annual Meeting did not support the addition of sorafenib to gemcitabine therapy in the treatment of advanced pancreatic cancer (APC), in contrast to an earlier Phase I study that demonstrated that this combination was well tolerated and had activity in APC patients.
View full resource at empr.com
Tags: Pancreatic Disease, Cancer, Cancer Medication, Pancreatic Cancer, Gemzar, Education
Most Recently Shared on June 6, 2011 at 9:01 pm By:
#asco2011 Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced… http://goo.gl/fb/XYOKi
Advertisement
